Recent increase of breast cancer incidence among women under the age of forty

Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva, 55, bd de la Cluse, 1205 Geneva, Switzerland.
British Journal of Cancer (Impact Factor: 4.82). 07/2007; 96(11):1743-6. DOI: 10.1038/sj.bjc.6603783
Source: PubMed

ABSTRACT Using data from the Geneva Cancer Registry, we found that in 2002-2004, breast cancer incidence in women aged 25-39 years increased by 46.7% per year (95% CI: 7.1-74.0, P=0.015), which surveillance or detection bias may not fully explain.


Available from: Isabelle Neyroud-Caspar, May 30, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Young age at diagnosis has a negative prognostic impact on outcome in patients with breast cancer (BC). In the current study, the authors sought to determine whether there is a differential effect of race and examined mortality trends according to race and age. The Surveillance, Epidemiology, and End Results program was used to identify women aged <50 years with invasive BC diagnosed between 1990 and 2009. Multivariate regression analyses were performed to determine the risk-adjusted likelihood of survival for white and black patients. Annual hazards of BC death according to race and calendar period and adjusted relative hazards of death for white and black women stratified by age were computed. A total of 162,976 women were identified, 126,573 of whom were white, 20,405 of whom were black, and 15,998 of whom were of other races. At a median follow-up of 85 months, the 5-year disease specific survival rates were 90.1% for white patients and 79.3% for black patients. Annual hazards of death in white patients decreased by 26% at 5 years after diagnosis in contrast to the hazards in black patients, which decreased by only 19%. With 1990 as the referent year, the adjusted relative hazards of death in women aged <40 years in 2005 were 0.55 (95% confidence interval [95% CI], 0.46-0.66) and 0.68 (95% CI, 0.49-0.93), respectively, for white and black women. In women aged 40 to 49 years, adjusted hazards of death were 0.53 (95% CI, 0.47-0.60) and 0.78 (95% CI, 0.61-0.99), respectively, for white and black women. Among young women diagnosed with BC, black patients have a worse outcome compared with white patients. Mortality declines have been observed over time in both groups, although more rapid gains have been reported to occur in white women. Emphasis should be placed on improving outcomes for young patients with BC. Cancer 2014. © 2014 American Cancer Society. © 2014 American Cancer Society.
    Cancer 12/2014; 121(9). DOI:10.1002/cncr.29178 · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer (BC) is the most commonly diagnosed cancer and a leading cause of death in younger women. We analysed incidence, mortality and relative survival (RS) in women with BC aged 20-49 years at diagnosis, between 1996 and 2009 in Switzerland. Trends are reported as estimated annual percentage changes (EAPC). Our findings confirm a slight increase in the incidence of BC in younger Swiss women during the period 1996-2009. The increase was largest in women aged 20-39 years (EAPC 1.8%). Mortality decreased in both age groups with similar EAPCs. Survival was lowest among women 20-39 years (10-year RS 73.4%). We observed no notable differences in stage of disease at diagnosis that might explain these differences. The increased incidence and lower survival in younger women diagnosed with BC in Switzerland indicates possible differences in risk factors, tumour biology and treatment characteristics that require additional examination. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Breast (Edinburgh, Scotland) 12/2014; 24(2). DOI:10.1016/j.breast.2014.11.004 · 2.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: In order to evaluate the impact of collection procedure on stability of coagulation parameters, apheresis plasma (AP) prepared by two machines, (COBE Gambro (group I) and Autopheresis C / Baxter (group II), and recovered plasma (RP) , derived from whole blood (group III) were studied. Methods: Fifteen leukoreduced AP units of 500 ml, prepared by each machine, and RP prepared from bags stored at 4 °C for 3 (15 units) and 24 hours (15 units) after donation were studied. All aliquots were immediately frozen at -20 °C for batch analysis. The influence of twice freezing and thawing, and 24 hours storage of thawed plasma at 4 °C on coagulation parameters was evaluated. Results: With regard to collection procedure, significant impairment of all coagulation values was noted in RP compared to AP (P < 0.005). Immediately on thawing AP, no significant differences were noted between both machines with regard to coagulation values (P>0.05). When AP was twice frozen, a 45% drop of FV activity was noted with COBE, compared to a 30% drop with Auto C (P =0.04). When we studied the influence of storage conditions on coagulation profile, it was noted that RP prepared 24 hours after donation, showed a significant reduction of FVIII (median activity was 48%), compared to that prepared after 3 h (89%) (P < 0.005). Compared to immediately thawing values, twice frozen AP and RP showed significant impairment of all values, (P < 0.05). However, AP had good hemostatic profile, where the median values for Auto C and COBE were; PT, 13 and 16 seconds; PTT, 40 and 37 seconds; PC, 94 and 80%; INR, 1.03 and 1.2; fibrinogen, 200 and 240 mg/dl; FV, 100 and 95%; F VIII, 90 and 89%, respectively. The median values for RP prepared 3 and 24 h after donation were ; PT, 20 and 21 seconds; PTT, 75 and 88 seconds; PC, 45 and 40 %; INR, 1.8 and 2; fibrinogen, 190 and 200 mg/dl; FV, 20 and 7%; F VIII, 30 and 19%, respectively. Compared to immediately thawing values, values of thawed AP were not influenced by 24 h storage at 4°C (P > 0.05). Significant drop of FV was noted with RP stored at 4 °C for 24 hours (P < 0.005), associated with a significant increase in the APTT (P < 0.005). Conclusion: AP offers plasma with high quality. Factors were well preserved in AP when it was twice frozen or stored at 4 °C for 24 hours, making it clinically useful and cost efficient. Furthermore, AP offers the advantage of prestorage leukoreduction. Large doses could also be obtained reducing donor exposure. Twice frozen and 24 hours stored RP might not be an optimal product to use for patients, needing massive transfusion and those with deficient factor V or VIII , which could be a limiting factor for their clinical and economic benefits.